$VTAE Published On: Thu, Mar 10th, 2016
Stocks | By Sylvia Delisle
Vitae Pharmaceuticals, Inc. (VTAE) Analyst Updates
A number of investment brokers have recently updated their price targets on shares of Vitae Pharmaceuticals, Inc. (VTAE). According to the latest broker reports outstanding on Thursday 10th of March, 2 analysts have a rating of “strong buy”, 1 analysts “buy”, 2 analysts “neutral”, 0 analysts “sell” and 0 analysts “strong sell”.
Most recent broker ratings
03/04/2016 – Vitae Pharmaceuticals, Inc. was downgraded to “hold” by analysts at Stifel Nicolaus.
01/07/2016 – Vitae Pharmaceuticals, Inc. had its “overweight” rating reiterated by analysts at Piper Jaffray. They now have a USD 23 price target on the stock.
01/02/2016 – Vitae Pharmaceuticals, Inc. had its “outperform” rating reiterated by analysts at Wedbush. They now have a USD 20 price target on the stock.
12/03/2015 – Wells Fargo began new coverage on Vitae Pharmaceuticals, Inc. giving the company a “outperform” rating.
06/29/2015 – Vitae Pharmaceuticals, Inc. was downgraded to “market perform” by analysts at JMP Securities.
05/15/2015 – Vitae Pharmaceuticals, Inc. was downgraded to “hold” by analysts at Zacks.
12/09/2014 – Vitae Pharmaceuticals, Inc. had its “outperform” rating reiterated by analysts at BMO Capital Markets. They now have a USD 27 price target on the stock.
10/20/2014 – EVA Dimensions began new coverage on Vitae Pharmaceuticals, Inc. giving the company a “hold” rating.
The share price of Vitae Pharmaceuticals, Inc. (VTAE) was up +3.33% during the last day of trading, with a day high of 4.73. 592581 shares were traded during the last session.
The stock’s 50 day moving average is 8.98 and its 200 day moving average is 12.11. The stock’s market capitalization is 101.70M. Vitae Pharmaceuticals, Inc. has a 52-week low of 4.15 and a 52-week high of 18.71.
Vitae Pharmaceuticals, Inc. is a clinical stage biotechnology company focused on discovering and developing small molecule drugs for diseases where there are unmet medical needs. The Company is developing a portfolio of product candidates generated by Contour, its structure-based drug discovery platform. The Company has two partnered product candidates in the clinic and several wholly owned drug candidates in preclinical development. The Company’s two partnered product candidates are VTP-34072, which is in a Phase II clinical trial for the treatment of type 2 diabetes, and BI 1147560 for the treatment and prevention of Alzheimer’s disease. The Company’s several wholly owned product candidates advancing in preclinical development, including VTP-43742 for the treatment of autoimmune disorders, VTP-38543 for the treatment of atopic dermatitis and VTP-38443 for the treatment of acute coronary syndrome.
View other investors thoughts on Vitae Pharmaceuticals, Inc. with our new Stock Talk discussion platform. Sign up for free to contribute to the community and view research provided from other investors for any stock listed on the LSE, NYSE or NASDAQ.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.
Stocks | By Sylvia Delisle
Vitae Pharmaceuticals, Inc. (VTAE) Analyst Updates
A number of investment brokers have recently updated their price targets on shares of Vitae Pharmaceuticals, Inc. (VTAE). According to the latest broker reports outstanding on Thursday 10th of March, 2 analysts have a rating of “strong buy”, 1 analysts “buy”, 2 analysts “neutral”, 0 analysts “sell” and 0 analysts “strong sell”.
Most recent broker ratings
03/04/2016 – Vitae Pharmaceuticals, Inc. was downgraded to “hold” by analysts at Stifel Nicolaus.
01/07/2016 – Vitae Pharmaceuticals, Inc. had its “overweight” rating reiterated by analysts at Piper Jaffray. They now have a USD 23 price target on the stock.
01/02/2016 – Vitae Pharmaceuticals, Inc. had its “outperform” rating reiterated by analysts at Wedbush. They now have a USD 20 price target on the stock.
12/03/2015 – Wells Fargo began new coverage on Vitae Pharmaceuticals, Inc. giving the company a “outperform” rating.
06/29/2015 – Vitae Pharmaceuticals, Inc. was downgraded to “market perform” by analysts at JMP Securities.
05/15/2015 – Vitae Pharmaceuticals, Inc. was downgraded to “hold” by analysts at Zacks.
12/09/2014 – Vitae Pharmaceuticals, Inc. had its “outperform” rating reiterated by analysts at BMO Capital Markets. They now have a USD 27 price target on the stock.
10/20/2014 – EVA Dimensions began new coverage on Vitae Pharmaceuticals, Inc. giving the company a “hold” rating.
The share price of Vitae Pharmaceuticals, Inc. (VTAE) was up +3.33% during the last day of trading, with a day high of 4.73. 592581 shares were traded during the last session.
The stock’s 50 day moving average is 8.98 and its 200 day moving average is 12.11. The stock’s market capitalization is 101.70M. Vitae Pharmaceuticals, Inc. has a 52-week low of 4.15 and a 52-week high of 18.71.
Vitae Pharmaceuticals, Inc. is a clinical stage biotechnology company focused on discovering and developing small molecule drugs for diseases where there are unmet medical needs. The Company is developing a portfolio of product candidates generated by Contour, its structure-based drug discovery platform. The Company has two partnered product candidates in the clinic and several wholly owned drug candidates in preclinical development. The Company’s two partnered product candidates are VTP-34072, which is in a Phase II clinical trial for the treatment of type 2 diabetes, and BI 1147560 for the treatment and prevention of Alzheimer’s disease. The Company’s several wholly owned product candidates advancing in preclinical development, including VTP-43742 for the treatment of autoimmune disorders, VTP-38543 for the treatment of atopic dermatitis and VTP-38443 for the treatment of acute coronary syndrome.
View other investors thoughts on Vitae Pharmaceuticals, Inc. with our new Stock Talk discussion platform. Sign up for free to contribute to the community and view research provided from other investors for any stock listed on the LSE, NYSE or NASDAQ.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.
I'm in it to win it!
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
